1. Home
  2. TBBK vs IBRX Comparison

TBBK vs IBRX Comparison

Compare TBBK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • IBRX
  • Stock Information
  • Founded
  • TBBK 1999
  • IBRX 2014
  • Country
  • TBBK United States
  • IBRX United States
  • Employees
  • TBBK N/A
  • IBRX N/A
  • Industry
  • TBBK Major Banks
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TBBK Finance
  • IBRX Health Care
  • Exchange
  • TBBK Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • TBBK 2.6B
  • IBRX 2.4B
  • IPO Year
  • TBBK 2004
  • IBRX N/A
  • Fundamental
  • Price
  • TBBK $55.17
  • IBRX $4.49
  • Analyst Decision
  • TBBK Buy
  • IBRX Buy
  • Analyst Count
  • TBBK 3
  • IBRX 2
  • Target Price
  • TBBK $55.00
  • IBRX $17.38
  • AVG Volume (30 Days)
  • TBBK 749.3K
  • IBRX 10.4M
  • Earning Date
  • TBBK 10-24-2024
  • IBRX 11-12-2024
  • Dividend Yield
  • TBBK N/A
  • IBRX N/A
  • EPS Growth
  • TBBK 16.50
  • IBRX N/A
  • EPS
  • TBBK 3.95
  • IBRX N/A
  • Revenue
  • TBBK $472,068,000.00
  • IBRX $7,332,000.00
  • Revenue This Year
  • TBBK N/A
  • IBRX $1,563.18
  • Revenue Next Year
  • TBBK $7.93
  • IBRX $1,262.20
  • P/E Ratio
  • TBBK $13.97
  • IBRX N/A
  • Revenue Growth
  • TBBK 6.73
  • IBRX 1218.71
  • 52 Week Low
  • TBBK $29.92
  • IBRX $3.10
  • 52 Week High
  • TBBK $59.46
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 53.12
  • IBRX 46.07
  • Support Level
  • TBBK $53.16
  • IBRX $4.57
  • Resistance Level
  • TBBK $59.46
  • IBRX $5.08
  • Average True Range (ATR)
  • TBBK 2.20
  • IBRX 0.54
  • MACD
  • TBBK 0.37
  • IBRX -0.12
  • Stochastic Oscillator
  • TBBK 62.73
  • IBRX 3.16

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Share on Social Networks: